Recorded 07/07/26Senior analyst Ritu Baral hosts Dr. Scott Aaronson, Chief Science Officer for Advanced Diagnostics and Therapeutics at Sheppard Pratt Health System, to discuss operations at a nonprofit/academic interventional psychiatry clinic and how the model may evolve as new psychedelic treatment modalities, including psilocybin-based therapies, move closer to potential approval.Dr. Aaronson underscores the substantial unmet need in TRD, noting that these are highly ill patients with meaningful morbidity and mortality risk, making durability and the ability to re-dose clinically important. He notes that current interventional options offered at his clinic, including ECT and TMS, remain constrained by reimbursement, staffing, and site-of-care economics, with hospital-based settings generally better positioned than private practices to absorb monitoring and overhead costs. Looking ahead, he sees clinical utility for psilocybin-based therapies such as COMP360, while highlighting key implementation questions around reimbursement feasibility, supervised dosing infrastructure, preparation/integration requirements, and rigorous patient screening for psychosis risk as access expands.